Mesangial proliferative glomerulonephritis with aldosterone-producing adenoma

被引：0

作者：

Tanemoto M. ^{[1
]}

Abe M. ^{[1
]}

Satoh F. ^{[1
]}

Abe T. ^{[1
]}

Satoh H. ^{[1
]}

Ito S. ^{[1
]}

机构：

[1] Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi 980-8574

来源：

Clinical and Experimental Nephrology | 2007年 / 11卷 / 2期

关键词：

Aldosterone-producing adenoma; Mesangial proliferative glomerulonephritis; Primary aldosteronism; Renin-angiotensin-aldosterone cascade;

D O I：

10.1007/s10157-007-0460-0

中图分类号：

学科分类号：

摘要：

We describe a case of mesangial proliferative glomerulonephritis (MesPGN), the clinical symptoms of which were exacerbated by aldosterone-producing adenoma (APA). A 45-year-old man, who had had a history of hypertension for several years, presented with renal derangement, with serum creatinine at its upper normal limit and with microhematuria and proteinuria. He also presented with hypokalemia, with a plasma aldosterone concentration at its upper normal limit and plasma renin activity at its lower normal limit. After the administration of spironolactone, we resected his left adrenal gland, which had a nodular lesion as well as aldosterone hypersecretion. The treatment normalized his arterial blood pressure and serum potassium concentration. Although his proteinuria disappeared with the reduction in arterial blood pressure, the microhematuria continued. The administration of losartan because of the histological finding of MesPGN reduced the amount of hematuria. A dissociated response of hematuria and proteinuria to antihypertensive treatment indicated that MesPGN was coincidental with APA. © 2007 Japanese Society of Nephrology.

引用

页码：164 / 167

页数：3

共 25 条

[1]

Sinclair A.M., Isles C.G., Brown I., Cameron H., Murray G.D., Robertson J.W., Secondary hypertension in a blood pressure clinic, Arch Intern Med, 147, pp. 1289-93, (1987)

[2]

Danielson M., Dammstrom B., The prevalence of secondary and curable hypertension, Acta Med Scand, 209, pp. 451-5, (1981)

[3]

Young Jr. W.F., Minireview. Primary aldosteronism: Changing concepts in diagnosis and treatment, Endocrinology, 144, pp. 2208-13, (2003)

[4]

Ganguly A., Primary aldosteronism, N Engl J Med, 339, pp. 1828-34, (1998)

[5]

Donadio J.V., Grande J.P., IgA nephropathy, N Engl J Med, 347, pp. 738-48, (2002)

[6]

Schocklmann H.O., Lang S., Sterzel R.B., Regulation of mesangial cell proliferation, Kidney Int, 56, pp. 1199-207, (1999)

[7]

Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1850 biopsied cases, Nephron, 82, pp. 205-13, (1999)

[8]

Li L.S., Liu Z.H., Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13 519 renal biopsies, Kidney Int, 66, pp. 920-3, (2004)

[9]

Gesualdo L., Di Palma A.M., Morrone L.F., Strippoli G.F., Schena F.P., The Italian experience of the national registry of renal biopsies, Kidney Int, 66, pp. 890-4, (2004)

[10]

Simon P., Ramee M.P., Boulahrouz R., Stanescu C., Charasse C., Ang K.S., Et al., Epidemiologic data of primary glomerular diseases in western France, Kidney Int, 66, pp. 905-8, (2004)

← 1 2 3 →